Background: Poor responders impose a great challenge to ART clinicians. Research to improve their pregnancy rate is going on. This study was conducted to analyze the effect of growth hormone in poor responders in ART.Methods: This study was done from January 2015 to December 2015. It was a retrospective, single centre, cohort study in which 36 poor responders were selected and allotted into group A (18) with growth hormone and group B (18) without growth hormone. High dose of gonadotrophins was used for ovarian stimulation and antagonist protocol was followed in all patients. Group A received 4 IU of growth hormone along with usual treatment from day 2 till ovulation trigger with HCG injection, group B usual protocol.Results: Statistical analysis was done with independent T test, and p value <0.05 was considered significant. Higher number of mature oocytes and pregnancy rates were observed in growth hormone group. Number of MII oocytes was 5.8, on an average in group A and 3.7 in group B, the difference was statistically significant (p 0.0000001).  Clinical pregnancy rates were 27.7% in group A and 16.6% in group B, statistical significance (p 0.02).Conclusions: Addition of growth hormone shows increase in number of oocytes retrieved and pregnancy rates in poor responders in ART patients.

Background: Anemia due to Iron deficiency is the commonest malnutrition disorder seen throughout the world and in India. It is also responsible for increased incidence of premature births, low birth weight babies and high perinatal mortality. Hence, the present study undertaken to assess efficacy and safety of injectable iron sucrose with oral ferrous ascorbate.Methods: 100 pregnant women, between gestational age 14 and 28 weeks were divided randomly into two groups i.e. group A consists of oral iron, a total of 200 mg of elemental iron per day, two 100mg iron tablets per day and group B consists of iron sucrose at the rate of 200mg on alternate OPD day. Informed consent was taken from each patient.Results: The percentage rise in hemoglobin at fourth and eighth weeks of treatment was statistically significant when compared to the baseline. Statistically significant rise in hemoglobin, PCV and ferritin levels were found at fourth and eighth weeks in IV group when compared to oral group.Conclusions: This study concluded that intravenous iron sucrose is safe and highly efficacious for the treatment of anemia in pregnancy. It restores iron stores more promptly. Iron sucrose therapy is more effective in achieving the optimum results, an increase in hemoglobin concentration, PCV levels and an increase in ferritin levels also. Therefore, it is a suitable alternative to oral iron with minimal side effects in those patients who cannot tolerate oral iron therapy.